Loading clinical trials...
Loading clinical trials...
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Conditions
Interventions
Evolocumab
Placebo
Locations
15
United States
Research Site
Miami, Florida, United States
Research Site
Las Vegas, Nevada, United States
Research Site
Mooresville, North Carolina, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Hurst, Texas, United States
Research Site
Newmarket, Ontario, Canada
Start Date
April 14, 2016
Primary Completion Date
April 5, 2018
Completion Date
April 5, 2018
Last Updated
September 23, 2022
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions